Copenhagen, Denmark; November 20, 2007 - Pursuant to Section 28a of the Danish
Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on
transactions by managerial employees and their related parties involving Genmab
shares and related instruments, as follows:
Name: Hans Henrik Munch-Jensen
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Shares
Transaction: Buy
Trading date: November 19, 2007
Market: OMX Nordic Exchange Copenhagen A/S
Number: 300
Market value: DKK 93,750
Name: Mimi Munch-Jensen
Reason: Daughter of Board Member Hans Henrik Munch-Jensen
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Shares
Transaction: Buy
Trading date: November 19, 2007
Market: OMX Nordic Exchange Copenhagen A/S
Number: 150
Market value: DKK 46,875
Name: Minna Munch-Jensen
Reason: Daughter of Board Member Hans Henrik Munch-Jensen
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Shares
Transaction: Buy
Trading date: November 19, 2007
Market: OMX Nordic Exchange Copenhagen A/S
Number: 150
Market value: DKK 46,875
Name: Amalie Munch-Jensen
Reason: Daughter of Board Member Hans Henrik Munch-Jensen
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Shares
Transaction: Buy
Trading date: November 19, 2007
Market: OMX Nordic Exchange Copenhagen A/S
Number: 150
Market value: DKK 46,875
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using unique,
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances towards a commercial future, we remain committed to our
primary goal of improving the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 54/2007
###
Attachments
Recommended Reading
-
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants...
Read More -
Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The...
Read More